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Abstract 3-Bromopyruvate (3BP) is an energy-depleting
drug that inhibits Hexokinase II activity by alkylation during
glycolysis, thereby suppressing the production of ATP and
inducing cell death. As such, 3BP can potentially serve as an
anti-tumorigenic agent. Our previous research showed that
3BP can induce apoptosis via AKT /protein Kinase B signal-
ing in breast cancer cells. Here we found that 3BP can also
induce colon cancer cell death by necroptosis and apoptosis at
the same time and concentration in the SW480 and HT29 cell
lines; in the latter, autophagy was also found to be a mecha-
nism of cell death. In HT29 cells, combined treatment with
3BP and the autophagy inhibitor 3-methyladenine (3-MA)
exacerbated cell death, while viability in 3BP-treated cells
was enhanced by concomitant treatment with the caspase in-
hibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone
(z-VAD-fmk) and the necroptosis inhibitor necrostatin
(Nec)-1. Moreover, 3BP inhibited tumor growth in a SW480
xenograft mouse model. These results indicate that 3BP can
suppress tumor growth and induce cell death by multiple
mechanisms at the same time and concentration in different
types of colon cancer cell by depleting cellular energy stores.












RIP1 Receptor-interacting protein 1
RIP3 Receptor-interacting protein 3
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MCTs Monocarboxylate transporters





PBS Phosphate Buffered Saline
DMSO Dimethylsulfoxide
DMEM Dulbecco’s Modified Eagle’s Medium
DNR Daunorubicin
Introduction
Colorectal cancer (CRC) is the third most diagnosed cancer
worldwide, and there has been extensive research on anti-
tumorigenic drugs for its treatment (Jemal et al. 2011). CRC
is typically treated by surgical resection and postoperative
adjuvant radio- and chemotherapy. However, the latter is as-
sociated with strong side effects and dose-limiting toxicity. As
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such, there is ongoing need for developing less toxic but still
effective drugs to treat CRC.
The Warburg effect posits that tumor cells depend on gly-
colysis to generate ATP even in the presence of oxygen
(Warburg 1956). The enzyme hexokinase (HK), a key glyco-
lytic enzyme, is overexpressed in tumor cells and is inhibited
by 3-bromopyruvate (Cardaci et al. 2012; da-Silva et al.
2004). It is putative that proton-linked monocarboxylate trans-
porters (MCTs) mediate 3BP uptake. 3BP mediate
pyruvylation of GAPDH which decrease ATP and anabolic
precursors. Pyruvylated GAPDH could elicite the pro-
apoptotic effects after translocating into the nucleus
phenocoping (Cardaci et al. 2012). Inhibition of hexokinase-
II by 3BP decreases ATP and NADPH levels, thereby
blocking glycolysis in tumor cells and slowing or halting their
growth (Chen et al. 2009; Chesney et al. 1999; Galluzzi et al.
2012). 3-BrPA mediated impairment of succinate dehydroge-
nase (SDH) activity lowers succinate-derived ATP levels and
increases ROS production (Cardaci et al. 2012).
Previous study (Leist et al. 1997) indicates that apoptosis is
a process depending on ATP, the lack of ATP would result in
cell necrosis. Research (Xu et al. 2005) reported cell deaths by
3BP contain apoptosis and necrosis. While massive depletion
of ATP leads to necrosis, a moderate decrease leads to induc-
tion of cellular autophagy to overcome situations of energetic
or metabolic stress (Shoshan 2012). The absence of ATP leads
to DNA degradation and ultimately to cell death (Parks et al.
2013). Moreover, mitochondrial permeability is increased by
inhibiting HK and the consequent release of cytochrome C
activates caspases that induce cellular apoptosis (Ferraro
et al. 2008; Zuo et al. 2011). Under apoptosis-deficient con-
ditions or upon infection by certain types of virus, receptor-
interacting protein (RIP)1 forms a complex with RIP3 to me-
diate necroptosis, which is characterized by the activation of
autophagy with necrotic features. The formation of this com-
plex requires RIP1 kinase activity, which is inhibited by the
small molecule Nec-1 (Degterev et al. 2005; Yuan and Kroe-
mer 2010).
Three forms of cell death are recognized, including apopto-
sis, cell death associated with autophagy, and necrosis. The
latter is typically unregulated, whereas apoptosis and autoph-
agic cell death are considered as two types of programmed cell
death (Galluzzi et al. 2012). However, an increasing number
of studies have demonstrated that necrosis can also be regu-
lated in a process known as necroptosis (Cho et al. 2009; He
et al. 2009; Zhang et al. 2009a). Morphological features of
apoptotic cells are chromatin condensation leading to pyknot-
ic nuclei (Schweichel andMerker 1973) and the close packing
of cytoplasmic organelles resulting from a loss of cytosol
(Bellairs 1961). Autophagic cells are characterized by the ap-
pearance of autophagic vacuoles in the cytoplasm. The con-
version of microtubule-associated protein 1 light chain (LC)3-
Ito LC3-IIin the membranes of autophagic bodies is widely
used as an autophagosomemarker (Kabeya et al. 2000; Tanida
et al. 2004; Zhang et al. 2014). Autophagy can be specifically
inhibited by 3-MA. Necroptotic cells exhibit a breakdown of
the cell membrane and swelling of cellular organelles (He
et al. 2009).
Our previous work found that 3BP can induce apoptosis via
AKTsignaling in breast cancer cells (Liu et al. 2014). This was
investigated in the present study using SW480 and HT29 hu-
man colon carcinoma cell lines. The results showed that 3BP
induces multiple forms of cell death by energy depletion
in vitro, which is beneficial to reduce the resistance of the
single cell death form by drugs, providing a potential treatment
for a special cells, and 3BP possesses anti-tumor ability in vivo,
suggesting that 3BP can be used in the treatment of CRC.
Materials and methods
Reagents and antibodies
The compounds 3BP, 3-MA, 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT), and Nec-1 were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). The cas-
pase inhibitor z-VAD-fmk was purchased from Calbiochem
(San Diego, CA, USA). The JC-1(5,5′,6,6′-tetrachloro-1,1′,3,
3′-tetraethyl-benzimidazolylcarbocyanine iodide) and PI as-
say kits were purchased from Beyotime Institute of Biotech-
nology (Wuhan, China) and the ATP Assay kit was from
Merck KGaA (Darmstadt, Germany) and An Annexin V
FITC/propidium iodide (PI) apoptosis detection kit was pur-
chased from Nanjin KeyGen Biotech (Nanjing, China). The
enzyme-linked immunosorbent assay kit for Hexokinase II
was purchase from Cloud-Clone Crop (Houston, TX, USA).
The following antibodies were used: rabbit monoclonal anti-
bodies against X-linked inhibitor of apoptosis protein (XIAP),
cellular inhibitor of apoptosis protein (cIAP)1 (both from
Bioss, Hong Kong, China), and cIAP2 (Abgent, Suzhou, Chi-
na); monoclonal antibodies against LC3, Bcl-2-associated X
protein (Bax), myeloid cell leukemia (Mcl)-1, and B cell CLL/
Lymphoma (Bcl)-2 protein (all from Proteintech, Chicago, IL,
USA); and rabbit monoclonal antibodies against RIP1 and 3
and β-actin and HKII(Santa Cruz Biotechnology, Santa Cruz,
CA, USA); Anti-monocarboxylate transporter (MCT)1 anti-
body and rabbit anti-monocarboxylate transporter (MCT)4
were obtained from Millipore (Temecula, CA, USA); Anti-
monocarboxylate transporter (MCT)2 was form Abcam
(Cambridge, MA, USA). All reagents were dissolved accord-
ing to the manufacturer’s instructions.
Cell culture
Human colon carcinoma SW480 and HT29 cells were obtain-
ed from the American Type Culture Collection (Manassas,
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VA, USA) and were passaged for less than half a year. Cells
were grown in high-glucose Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10 % fetal bovine se-
rum, 100 U/ml penicillin, and 100 μg/ml streptomycin at
37 °C in 95 % air and 5 % CO2.
MTTassay
Cells were seeded in a 96-well plate at a density of 6×103 cells
per well and treated with different concentrations of 3BP. At
24, 48, and 72 h, MTT (5 mg/ml in phosphate-buffered saline,
PBS) was added for 4 h at 37 °C. After 4 h, the solution was
replaced with 150 μl of dimethylsulfoxide (DMSO, Biosharp,
Hefei, China) and 30 min later, cell viability was determined
by measuring absorbance at a wavelength of 490 nm using a
microplate reader (Synergy HT, BioTek, Vermont, U.S.A).
Colony formation assay
Cells were seeded in 6-well plates at 1×105 cells per well and
incubated for 24 h, then treated with various concentrations of
3BP for 24 h. The medium was replaced with 2 ml fresh
medium and cells were cultured for 5 more days, then fixed
with paraformaldehyde for 10 min at −20 °C followed by
staining with 2 % crystal violet for 20 min.
Flow cytometry
Prior to 3BP treatment, 2×105 cells per well were seeded in a
12-well plate for 24 h. At exponential growth phase, cells
were treated with different concentrations of 3BP (40, 80,
160, and 320 μmol/L) for 24 h, which was followed by PI
staining and Accuri C6 flow cytometry (BD Biosciences,
State of New Jersey, U.S.A). In addition, annexin-V FITC/PI
staining was carried out according to the manufacturer’s in-
structions to detect cellular apoptosis.
Nuclear staining
Cells (2×106) were seeded in a 6-well plate for 24 h until
exponential growth phase, then treated with 3BP (0, 40, 80,
160, and 320 μmol/L) for 48 h. Cells were harvested and
washed twice with cold PBS, then fixed with 4 % ethanol
for 30 min at room temperature, followed by two washes with
PBS and a 1 min incubation in 100 μl of DAPI solution
(2 μg/ml). Cell morphology was evaluated using a IX71 fluo-
rescencemicroscope (Olympus, Tokyo, Japan). Cells showing
chromatin condensation and nuclear fragmentation were de-
termined to be apoptotic.
Determination of ATP
ATP levels were measured using a luminescence-based ATP
Assay kit. The assay uses luciferase to catalyze the generation
of a fluorescent signal from ATP, luciferin, and oxygen; with
the degree of fluorescence proportional to the amount of ATP.
Cells (2×105) seeded in a 12-well plate for 24 h, were incu-
bated with various concentrations of 3BP for 5 h at 37 °C, with
untreated cells serving as a control group. After incubation,
cells were collected and homogenized in RIPA lysis buffer for
10 min on ice. Cell lysates were centrifuged at 13,225×g for
5 min at 4 °C. 100 μl of nucleotide-releasing buffer per well
and 1μl ATP-monitoring enzyme per well were added to a 96-
well plate, 30 μl of each suspension were transferred to each
well; and after a 60 s incubation at 25 °C, the signal was
measured using a Luminoskan luminometer (Thermo Scien-
tific, Atlanta, GA, USA).
Determination of mitochondrial membrane potential
Cells were seeded at a density of 2×105 cells per well in 12-
well-plates and treated with various concentrations of 3BP.
After 24 h, changes in mitochondrial membrane potential
were determined by staining cells with the cationic dye JC-1
using a kit according to the manufacturer’s instructions. Green
and red fluorescence was detected on the 1 and 2 channels,
respectively, of an IX71 fluorescence microscope.
Western blot analysis
Cells were collected and homogenized in RIPA lysis buffer
for 30 min on ice. Cell lysates were centrifuged at 13,225×g
for 30 min at 4 °C. Proteins were separated on a 12 %
sodium dodecyl sulfate polyacrylamide gel and transferred
to a nitrocellulose membrane (Universal Hood II, BioRad
Laboratories, Hercules, CA, U.S.A), which was incubated
with primary antibodies overnight at 4 °C followed by the
appropriate secondary antibody, with β-actin used as a
loading control.
Enzyme-linked immunosorbent assay kit for Hexokinase
II
Cells were seeded at a density of 2×105 cells per well in 12-
well-plates and treated with various concentrations of 3BP for
24 h at 37 °C, with untreated cells serving as a control group.
After incubation, cells were collected and homogenized in
1 % triton-100 for 10 min on ice. Cell lysates were centrifuged
at 1000×g for 20min at 4 °C. Detect the concentration of HKII
according to the manufacturer’s instructions.
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Evaluation of cell death type by electron microscopy
Cells were fixed with 3 % glutaraldehyde and 2 % parafor-
maldehyde in 0.1 M PBS (pH 7.4) overnight at 4 °C, then
postfixed with 1 % osmium tetroxide for 1.5 h, washed, and
stained with 3 % aqueous uranyl acetate for 1 h before dehy-
dration in a graded series of ethanol and acetone and embed-
ding in Araldite. Ultrathin sections were cut on a Reichert
ultramicrotome (Leica, Wetzlar, Germany), stained with
0.3 % lead citrate, and analyzed by TEM (Olympus JEOL,
Peabody, MA, USA).
Xenograft model
Female nude mice (BALB/c) 4–5 weeks of age and weighing
18–20 g were purchased from the animal experimental center
of Beijing vitalriver and maintained under specific pathogen-
free conditions. The experimental protocol was approved by
the ethics committee of Bengbu Medical College and was
carried out in accordance with the Guidance and Suggestions
for the Care and Use of Laboratory Animals published by The
Ministry of Science and Technology of China. SW480 cell
suspensions with >90 % viability were used for injections.
Mice were grafted subcutaneously in the left flank with 107
cells resuspended in 0.2 ml sterile DMEM. Mice were ran-
domized into 3BP (8 mg/kg), DNR positive control
(0.8 mg/kg), and PBS negative control groups (n=5 per
group) when tumor volume reached approximately
100 mm3. Group the implantation model using stratified ran-
dom grouping according to the tumor size. Tumors were mea-
sured with a caliper and volume was calculated using the
formula: 0.5×a×b2, where a and b are tumor length and
width, respectively. Tumors were stored in 4 % formalin so-
lution, embedded in paraffin, and cut into sections that were
stained with hematoxylin and eosin (H & E).
Statistical analysis
Independent experiments were performed in triplicate. Data
are expressed as the mean ± SEM of three experiments. SPSS
v.16.0 software (SPSS Inc., Chicago, IL, USA) was used for
data analysis. Half-maximal inhibitory concentration (IC50)
was calculated by probit regression analysis. Mean differences
were evaluated by t-test analysis of variance. *p<0.05 was
considered statistically significant.
Results
3BP selectively inhibits colon cancer cell viability
SW480 cells had greater sensitivity to 3BP than HT29
cells, and viability decreased in a dose-dependent manner
(Fig. 1a and b). In addition, colony formation in both cell
types was inhibited by increasing concentrations of 3BP
(10–50 μmol/L) (Fig. 1c), indicating that 3BP efficiently
inhibits colon cancer cell growth.
3BP lowers HKII level and mediate MCTs
ELISA results suggested that HKII was reduced as the 3BP
concentration dependence (Fig. 2a). Cellular ATP levels was
reduced by treatment with 3BP (Fig. 2b). These data indicate
that and induces cell death by decrease ATP level. Western
blotting results showed that with the increase of concentra-
tions of 3BP the expression of MCT1, MCT2 and HKIIwas
reduced, in turn MCT2 expression did not change basically
(Fig. 2c), The results indicated the 3BP transporters into colon
cancer cells through MCTs, influencing the expression of
HKII.
3BP induces apoptosis in colon cancer cells
JC-1 staining was used to detect mitochondrial membrane
potential (Fig. 3a). Treated cells exhibited condensed and
fragmented nuclei, which are indicative of apoptosis, and 4,
6-diamidine-20-phenylindole dihydrochloride (DAPI) stain-
ing (Fig. 3b), Annexin-V FITC/PI staining confirmed that
3BP induced apoptosis in SW480 and HT29 cells (Fig. 3c).
To investigate the mechanism by which 3BP induces cell
death, TEM examination revealed shrinkage, blebbing, nuclear
fragmentation, and chromatin condensation in apoptotic cells
(Fig. 4a); these effects were abolished by treatment with the
apoptosis inhibitor z-VAD-fmk (Fig. 4b). The induction of ap-
optosis in colon cancer cells by 3BP was confirmed by the
downregulation of XIAP, cIAP1, cIAP2,Mcl-1, and Bcl-2 pro-
tein levels and the upregulation of Bax protein level (Fig. 4c).
3BP induces necroptosis in colon cancer cells
Interesting, the TEM analysis revealed the presence of
necroptotic cells following 3BP treatment, which are charac-
terized by an absence of typical nuclear fragmentation, organ-
elle (especially mitochondrial) swelling, and loss of plasma
membrane integrity (Fig. 5a). The viability of 3BP-treated
cells was rescued by application of the necroptosis inhibitor
Nec-1 (Fig. 5b), as evidenced by the downregulation of RIP1
protein (Fig. 5c). These data indicate that 3BP induces
necroptosis in colon cancer cells.
3BP induces autophagy in colon cancer cells
Treatment with 3BP induced autophagy in HT29 cells, as
evidenced by the appearance of autophagic vacuoles in the
cytoplasm (Fig. 6a). The upregulation of LC3-II protein was
also observed in 3BP-treated cells (Fig. 6b), indicating that
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autophagy was induced. Inhibiting autophagy with 3-MA en-
hanced cell death in 3BP-treated cells, suggesting that autoph-
agy normally protects tumor cells against the cytotoxic effects
of 3BP (Fig. 6c).
3BP treatment inhibits tumor growth in a mouse model
The in vivo efficacy of 3BP was evaluated in a xenograft
mouse model generated by injecting SW480 cells into nude
mice. Treatment with PBS, 3BP (8 mg/kg) and daunorubicin
(DNR; 0.8 mg/kg) was initiated when tumor volume reached
approximately 100 mm3, 3BP prevented tumor growth
(Fig. 7a). On day 28, the average tumor volumes in 3BP and
DNR-treated groups (890±260, and 790±200 mm3,
respectively) were significantly lower than in vehicle-treated
control mice (1750±374mm3) (Fig. 7b). H&E staining of the
tumors showed that there were rich blood vessels and large
atypia nucleus in the tissue in control group, while chaotic
distribution of blood vessel, karyopyknosis, inflammatory cell
infiltration in experimental group, indicating 3BP induced ex-
tensive necrosis and inhibited tumor growth (Fig. 7c), provid-
ing evidence for its anti-tumorigenic action in vivo.
Discussion
Tumorigenesis is characterized by mitochondrial dysfunction,
hypoxia, tumor gene expression, and abnormal expression of
Fig. 1 3BP selectively inhibits
colon cancer cell viability. a
SW480 and HT29 cells were
treated with 40, 80, 160, or
320 μmol/L 3BP for 24, 48, or
72 h; cell viability was analyzed
by the MTT assay. b SW480 and
HT29 cells were treated with
various concentrations 3BP (80,
160, or 320 μmol/L) for 24 h and
morphology was examined by
light microscopy with differential
interference contrast optics.
Representative images are shown.
c SW480 cells were treated with 0
(A), 10 (B), 20 (C), or 30 (D)
μmol/L and HT29 cells were
treated with 0 (A), 30 (B), 40 (C),
or 50 (D) μmol/L 3BP for 5 days.
Data represent mean ± SEM of
three independent experiments
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metabolic enzymes (Warburg 1928). Tumor cells utilize ATP
generated by glycolysis, which is less efficient than oxidative
phosphorylation; as such, tumor cells consume more glucose
(i.e., have higher glycolytic activity) than normal cells. As
such, inhibiting glycolysis is a potential strategy for killing
cancer cells (Simonnet et al. 2002).
As an inhibitor of glycolysis, 3BP is known to have an anti-
tumorigenic function (Levy et al. 2012; Zhang et al. 2009b) in
liver and breast cancers and other malignant tumors
(Ganapathy-Kanniappan et al. 2010; Geschwind et al. 2002;
Liu et al. 2009; Ota et al. 2013). We provide here the evidence
for 3BP as an inhibitor colon cancer cell growth both in vitro
and in vivo, which is accomplished by multiple cell death
mechanisms, namely apoptosis, necroptosis, and autophagy
(Clarke 1990). Programmed cell death is executed via specific
intracellular biochemical pathways; apoptosis and necrosis are
two such mechanisms that play significant roles in develop-
ment and the maintenance of homeostasis in metazoans
(Festjens et al. 2006), and their dysregulation is linked to
various human diseases (Lockshin and Zakeri 2007).
Necroptosis is a programmed and regulated form of necrotic
cell death that is induced when a noxious stimulus is insuffi-
cient to trigger apoptosis in a cell. In such cases, tumor necro-
sis factor (TNF)-α activates TNF receptor (R) 1, which re-
cruits RIP1 and other factors to form complex I, consisting
of RIP1, RIP3, caspase-8, and Fas-associated death domain
protein. These proteins dissociate from TNFR1 and RIP1 and
are found in the cytosol as complex IIb, which is an effector of
necroptosis (Lukens et al. 2013; Thapa et al. 2013). Caspase
activation during apoptosis is accomplished through the ex-
trinsic and intrinsic pathways. The former is activated by the
binding of various cytokines such as TNF-α, TNF-related
apoptosis-inducing ligand, and cluster of differentiation 95
to their respective receptors, leading to caspase-8 activation
(Peter and Krammer 2003). The intrinsic pathway is activated
following the release of proteins such as cytochrome c and
Smac/Diablo from the mitochondrial intermembrane space
into the cytosol, which then activate caspase-9 and relieve
IAP-mediated inhibition of effector proteins (Du et al. 2000;
Li et al. 1997; Verhagen et al. 2000). Activated caspase-8 and
−9 subsequently cleave and activate several downstream
caspases including caspase-3 and -7, which in turn cleave
intracellular substrates, resulting in apoptosis.
Autophagy is a major intracellular pathway for the degrada-
tion and recycling of unused but long-lived proteins, damaged
organelles, and invasive pathogens (Mizushima and Komatsu
2011) that functions in several organs, including the brain,
heart, hematopoietic cells, and kidney (Komatsu et al. 2006;
Mortensen et al. 2011; Takahashi et al. 2012). Mice lacking
essential autophagy factors die within 1 day of birth (Kuma
et al. 2004). Although it is essential for normal cell function
and survival, autophagy can also be exploited by tumor cells
for treatment resistance (Jin and White 2008; Mathew and
White 2011). Activation of autophagy enhances cell survival
(Narendra et al. 2008), and therefore combining standard che-
motherapy with an autophagy inhibitor could potentially accel-
erate tumor cell death (Mathiasen and Jaattela 2002).
It is putative that proton-linked monocarboxylate trans-
porters (MCTs) mediate 3BP uptake. The expression of
MCT1 and MCT4 were decreased, possibly due to 3BP-
induced cell death, cell membrane cracking, resulting in lower
membrane transporters. We guess that inhibition of HKII by
3BP might decreases ATP levels, thereby blocking glycolysis
in tumor cells and slowing or halting their growth.
The results of this study showed that 3BP has potent inhib-
itory effects on colon cancer tumor growth that are compara-
ble to those of DNR. Interestingly, 3BP treatment induced
Fig. 2 3BP induces HKII and ATP reduction via MCTs transportation in
colon cancer cells. a SW480 and HT29 cells were treated with indicated
concentrations of 3BP for 24 h, andHKII level were assessed by Enzyme-
linked immunosorbent assay kit. b Intracellular ATP levels were
measured in SW480 and HT29 treated with 40, 80, 160, or 320 μmol/L
3BP for 5 h. control. c SW480 and HT29 cells treated with various
concentrations of 3BP for 24 h were subjected to HKII level and MCTs
by Western blot analysis, β-actin served as loading control. Data
represent mean ± SEM of three independent experiments. *p<0.05 vs
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Fig. 3 3BP-induced apoptosis in colon cancer cells. a SW480 and HT29
cells were treated with indicated concentrations of 3BP for 24 h, and the
mitochondrial membrane potential were assessed by JC-1 staining and
fluorescence microscopy. b SW480 and HT29 cells were treated with
indicated concentrations of 3BP for 48 h, and nuclei were stained with
DAPI and visualized by fluorescence microscopy. White arrowheads
indicate apoptotic cells. c SW480 and HT29 cells were treated with
indicated concentrations of 3BP for 24 h, and cells were determined
using flow cytometry of PI/Annexin V-stained cells. Data represent
mean ± SEM of three independent experiments
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Fig. 4 3BP-induced apoptosis in
colon cancer cells. a Electron
microscopy of cells treated for
24 h with Control, 160 or
320 μmol/L 3BP, white
arrowheads denote chromatin
pyknosis in the cells treated with
3BP. b Viability of SW480 or
HT29 cells treated with DMSO,
3BP (160 or 320 μmol/L), 3BP/z-
VAD (20 μmol/L, ) was analyzed
by MTT assay. Both cells were
pretreated with z-VAD 1 h before
treatment with 3BP/z-VAD. c
SW480 and HT29 cells treated
with various concentrations of
3BP for 24 h were subjected to
apoptosis-related proteins by
Western blot analysis, β-actin
served as loading control. Data
are representative of three
independent
experiments,*p<0.05
Fig. 5 3BP-induced necroptosis in colon cancer cells. a Electron
micrographs of cells treated for 24 h with 160 or 320 μmol/L 3BP or
the vehicle dimethylsulfoxide (DMSO; control). Black arrowheads
indicate cell membrane integrity in control cells and membrane
breakdown in 3BP-treated cells; white arrowheads indicate swelling of
cellular organelles in 3BP-treated cells. b SW480 or HT29 cell viability
following treatment with 3BP (160 or 320 μmol/L), 3BP/Nec-1
(20 μmol/L), or DMSO, as analyzed by the MTT assay. Both cells were
pretreated with Nec-1 1 h before treatment with 3BP/Nec-1. c SW480 and
HT29 cells treated with indicated concentrations of 3BP for 24 h were
analyzed for the expression of necroptosis-related proteins by western
blotting, with β-actin serving as a loading control. Data represent mean
± SEM of three independent experiments, *p<0.05
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autophagy in HT29 but not in SW480 cells; the reasons for
this difference between cells lines is unclear, and will require
further investigation. Moreover, the observation that the au-
tophagy inhibitor 3-MA potentiated 3BP-induced cell death
suggests that autophagy provides a survival advantage for
energy-depleted tumor cells. For instance, the necroptosis
inhibitor Nec-1 and z-VAD-fmk rescued cell viability that
was reduced by 3BP treatment. If cellular energy shortage is
exacerbated by suppressing the energy-generating glycolytic
pathway in HT29 cells, it is possible that autophagy is insuf-
ficient to rescue cells from irreversible cell death but could
enable tumor cells to survive.
Fig. 6 3BP-induced autophagy in colon cancer cells. a Electron
micrographs of HT-29 cells treated for 24 h with 320 μmol/L 3BP or
the vehicle dimethylsulfoxide (DMSO; control). White arrowheads
indicate autophagosomes. b HT29 cells treated with 3BP (320 μmol/L)
for 24 h were analyzed for the expression of autophagy-related proteins
by western blotting, with β-actin serving as loading control. c HT29 cell
viability following treatment with DMSO, 3BP (320 μmol/L), 3BP/3-
MA (5 mmol/L), as analyzed by the MTT assay. Cells were pretreated
with 3-MA 1 h before treatment with 3BP/3-MA. Data represent mean ±
SEM of three independent experiments, *p<0.05
Fig. 7 in vivo efficacy of 3BP in
a nude mouse model. a SW480
cells were subcutaneously
injected into the right flank of
mice receiving 200 μL vehicle,
3BP (8 mg/kg), or DNR
(0.8 mg/kg) treatment every
4 days by intraperitoneal
injection. Mice were sacrificed
after 28 days. b Representative
tumors from each treatment
group. Data represent mean ±
SEM (n=5). c H&E staining
in vivo
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The results of this study indicate that 3BP is a promising
anti-tumorigenic drug that functions by activating multiple
cell death pathways, and can potentially overcome tumor cell
resistance to chemotherapeutic agents that activate a single
cell death mechanism. Likewise, inhibiting glycolysis could
be a point of anti-multi-resistant treatment, it remains to be
subsequent research.
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